Business
Stratec : Publication Annual Report 2024
Stratec : Publication Annual Report
About this update from Stratec Se
FINANCIAL RESULTS FULL YEAR 2024 May 19, 2025 FY 2024 AT A GLANCE FINANCIAL REVIEW OUTLOOK Q&A HIGHLIGHTS AND ACHIEVEMENTS Progress in margins ahead of own expectations and strong cash flow dynamics despite challenging market environment Pipeline progress E.g. achievement of concluding development milestone for customer products in the field of transfusion diagnostics New cooperations agreed E.g. development cooperation in the field of immunodiagnostics aiming to rejuvenate an existing product (including additional functions) Strengthening of local presence Enhanced market position in Asia- Pacific and first sales synergies realized in the U.S. on the back of Natech acquisition Dividend proposal of € 0.60 per share (€ 0.55 in the prior year) FINANCIALS AT A GLANCE 1 € 000s FY 2024 FY 2023 2 Change Sales 257,624 270,414 -4.7 % (cc: -4.9%) Adjusted EBITDA 49,214 44,826 +9.8% Adjusted EBITDA margin (%) 19.1 16.6 +250 bps Adjusted EBIT 33,459 30,388 +10.1% Adjusted EBIT margin (%) 13.0 11.2 +180 bps Adjusted consolidated net income 20,496 19,009 +7.8% Adjusted basic earnings per share (in €) 1.69 1.56 +8.3% Basic earnings per share IFRS (in €) 1.32 1.26 +4.8% bps = basis points cc = at constant currency 1 For comparison purposes, adjusted figures have been adjusted to exclude amortization from purchase price allocations in the context of acquisitions, as well as for other one-off items (consulting and reorganization expenses in connection with M&A activities and one-off personnel expenses). 2 Restated in accordance with IAS 8. Attention : This is an excerpt of the original content. To continue reading it, access the original document here .